Emerging roles of flavin monooxygenase 3 in cholesterol metabolism and atherosclerosis

Current Opinion in Lipidology

Volumn 26, Issue 5, 2015, Pages 426-431

  Schugar, Rebecca C ^a   Brown, J Mark ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Atherosclerosis; Insulin resistance; Reverse cholesterol transport; Trimethylamine n oxide

Indexed keywords

CARNITINE; CHOLESTEROL; CHOLINE; FLAVIN MONOOXYGENASE 3; LIVER ENZYME; MICROBIAL ENZYME; PHOSPHATIDYLCHOLINE; TRIMETHYLAMINE; TRIMETHYLAMINE OXIDE; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE; DIMETHYLANILINE MONOOXYGENASE (N-OXIDE FORMING); OXYGENASE;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; ENZYME INHIBITION; INSULIN RESISTANCE; LIPID DIET; MACROPHAGE; NONHUMAN; NUTRIENT; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; ANIMAL; ENZYMOLOGY; HUMAN; LIPID METABOLISM; METABOLISM; PHYSIOLOGY;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; OXYGENASES;

EID: 84988735389     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000215     Document Type: Review

References (48)

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics - 2015 update: A report from the American Heart Association. Circulation 2015; 131:e29-e322.
2. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466:707-713.
3. Kathiresan S, Voight BF, Purcell S, et al. Genome-wide association of earlyonset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009; 41:334-341.
4. Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009; 41:56-65.
5. Deloukas P, Kanoni S, Willenborg C, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2013; 45:25- 33.
6. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-Associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444:1027-1031.
7. Koeth RA, Levison BS, Culley MK, et al. γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab 2014; 20:799-812.
8. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013; 19:576-585.
9. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368:1575- 1584.
10. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472:57-63.
11. Wang Z, Tang WH, Buffa JA, et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-Noxide. Eur Heart J 2014; 35:904-910.
12. Tang WH, Wang Z, Shrestha K, et al. Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. J Card Fail 2015; 21:916.
13. Al-Waiz M, Mikov M, Mitchell SC, et al. The exogenous origin of trimethylamine in the mouse. Metabolism 1992; 41:135-136.
14. Miller CA, Corbin KD, da Costa KA, et al. Effect of egg ingestion on trimethylamine-N-oxide production in humans: A randomized, controlled, dose-response study. Am J Clin Nutr 2014; 100:778-786.
15. Zeisel SH, Mar MH, Howe JC, et al. Concentrations of choline-containing compounds and betaine in common foods. J Nutr 2003; 133:1302-1307.
16. Bennett BJ, de Aguiar Vallim TQ, Wang Z, et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab 2013; 17:49-60.
17. Tabas I, Garcia-Cardena G, Owens GK. Recent insights into the cellular biology of atherosclerosis. J Cell Biol 2015; 209:13-22.
18. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: A dynamic balance. Nat Rev Immunol 2013; 13:709-721.
19. Hilgendorf I, Swirski FK, Robbins CS. Monocyte fate in atherosclerosis. Arterioscler Thromb Vasc Biol 2015; 35:272-279.
20. Lovren F, Teoh H, Verma S. Obesity and atherosclerosis: mechanistic insights. Can J Cardiol 2015; 31:177-183.
21. Brown JM, Hazen SL. Metaorganismal nutrient metabolism as a basis of cardiovascular disease. Curr Opin Lipidol 2014; 25:48-53.
22. Brown JM, Hazen SL. The gut microbial endocrine organ: Bacterially derived signals driving cardiometabolic diseases. Annu Rev Med 2015; 66:343- 359.
23. Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest 2014; 124:4204-4211.
24. Ussher JR, Lopaschuk GD, Arduini A. Gut microbiota metabolism of L-carnitine and cardiovascular risk. Atherosclerosis 2013; 231:456-461.
25. Cashman JR, Zhang J. Human flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol 2005; 46:65-100.
26. Siddens LK, Krueger SK, Henderson MC, et al. Mammalian flavin containing monooxygenase (FMO) as a source of hydrogen peroxide. Biochem Pharmacol 2014; 89:141-147.
27. Akerman BR, Lemass H, Chow LM, et al. Trimethylaminuria is caused by mutations of the FMO3 gene in a North American cohort. Mol Genet Metab 1999; 68:24-31.
28. Cashman JR, Bi YA, Lin J, et al. Human flavin-containing monooxygenase form 3: cDNA expression of the enzymes containing amino acid substitutions observed in individuals with trimethylaminuria. Chem Res Toxicol 1997; 10:873-941.
29. Treacy EP, Akerman BR, Chow LM, et al. Mutations of the flavincontaining monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication. Hum Mol Genet 1998; 7:839-845.
30. Zhang J, Tran Q, Lattard V, et al. Deleterious mutations in the flavincontaining monooxygenase 3 (FMO3) gene causing trimethylaminuria. Pharmacogenetics 2003; 13:495-500.
31. Fujieda M, Yamazaki H, Togashi M, et al. Two novel single nucleotide polymorphisms (SNPs) of the FMO3 gene in Japanese. Drug Metab Pharmacokinet 2003; 18:333-335.
32. Busby MG, Fischer L, da Costa KA, et al. Choline-And betaine-defined diets for use in clinical research and for the management of trimethylaminuria. J Am Diet Assoc 2004; 104:1836-1845.
33. Brugere JF, Borrel G, Gaci N, et al. Archaebiotics: proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular disease. Gut Microbes 2014; 5:5-10.
34. Bennett BJ, Orozco L, Kostem E, et al. High-resolution association mapping of atherosclerosis loci in mice. Atherscler Thromb Vasc Biol 2012; 32:1790- 1798.
35. Esposito T, Varriale B, D'Angelo R, et al. Regulation of flavin-containing monooxygenase (FMO3) gene expression by steroids in mice and humans. Horm Mol Biol Clin Investig 2014; 20:99-109.
36. Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: Structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 2005; 106:357-387.
37. Martinez-Del Campo A, Bodea S, Hamer HA, et al. Characterization and detection of a widely distributed gene cluster that predicts anaerobic choline utilization by human gut bacteria. MBio 2015; 6:e00042-15.
38. Gregory JC, Buffa JA, Org E, et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem 2015; 290:5647-5660.
39. Kayashima Y, Makhanova NA, Matsuki K, et al. Identification of aortic archspecific quantitative trait loci for atherosclerosis by an intercross of DBA/2J and 129S6 apolipoprotein E-deficient mice. PLoS One 2015; 10:e0117478.
40. Miao J, Ling AV, Manthena PV, et al. Flavin-containing monooxygenase 3 as a potential player in diabetes-Associated atherosclerosis. Nat Commun 2015; 6:6498.
41. Warrier M, Shih DM, Burrows AC, et al. The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance. Cell Rep 2015; 10:326-338.
42. Shih DM, Wang Z, Lee R, et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res 2015; 56:22-37.
43. Jeon TI, Esquejo RM, Roqueta-Rivera M, et al. An SREBP-responsive micro- RNA operon contributes to a regulatory loop for intracellular lipid homeostasis. Cell Metab 2013; 18:51-61.
44. Guttilla IK, White BA. Coordinate regulation of FOXO1 by miR-27a, miR- 96, and miR-182 in breast cancer cells. J Biol Chem 2009; 284:23204- 23216.
45. Kim KM, Park SJ, Jung SH, et al. miR-182 is a negative regulator of osteoblast proliferation, differentiation, and skeletogenesis through targeting FoxO1. J Bone Miner Res 2012; 27:1669-1679.
46. Stittrich AB, Haftmann C, Sgouroudis E, et al. The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes. Nat Immunol 2010; 11:1057-1062.
47. Marshall SM, Gromovsky AD, Kelley KL, et al. Acute sterol oacyltransferase 2 (SOAT2) knockdown rapidly mobilizes hepatic cholesterol for fecal excretion. PLoS One 2014; 9:e98953.
48. Temel RE, Sawyer JK, Yu L, et al. Biliary sterol secretion is not required for macrophage reverse cholesterol transport. Cell Metab 2010; 12:96102.